Research

Essays, research and public memos on the software and infrastructure behind biotech, pharma and life-science operations.

Our writing examines the markets and operating questions behind our investment thesis. We draw on operating experience, primary sources and conversations with the people who build and buy this software.

Published work

EssayOct 2, 2026AI is speeding up drug discovery. What happens next?Most AI effort in drug discovery still sits before the clinic, where the measurable cost leverage looks smaller than at Phase II, and the field still grades its models on metrics that say little about real development decisions.

What we study

How AI agents are changing scientific work: searching data, proposing designs and planning experiments, while people and robots run the lab work.
How labs connect design and testing, now that AI makes designs cheap and the physical experiment has become the bottleneck.
How automation, robotics and software carry science from the research bench to production.
How hospitals, care providers and life-science companies hand routine work to AI agents, such as scheduling, documentation, prior authorization and quality review, so their people can focus on the work that needs them.
How to make agents trustworthy in regulated work through human oversight, validation, audit trails and clear accountability.
How data from instruments, records and systems becomes ready for AI, and what it takes to trust it.
How regulation shapes products, purchasing and the pace of adoption in the US and Europe.
How small teams use AI to build what used to take large companies, and how that changes the way startups are built.
How early-stage companies win their first customers and turn pilots into lasting relationships.
What it takes for US and Nordic companies to expand across the Atlantic.

Have a perspective to share? Get in touch.

This research is for information only. It is not investment, legal or tax advice, or an offer or solicitation to buy any security, and it is not intended for investors or prospective investors in any Swea fund. Views are the author's as of the date shown, based on sources we believe reliable but have not verified, and may change. Mentioning a company doesn't mean Swea has invested or will invest in it, and Swea and its team may hold interests in companies discussed.